Mercedes Cano

Mercedes Cano

Auto-generated profile, based on publicly available information

Mercedes Cano


Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in Pharmacological Research
Verified
Journal Article
Closed access
RPRocío M. de Pablos
Rocío M. de Pablos
AEAna María Espinosa-Oliva
Ana María Espinosa-Oliva
RHRuth Hornedo-Ortega
Ruth Hornedo-Ortega
MCMercedes Cano
Mercedes Cano
SASandro Arguelles
Sandro Arguelles

13 July 2018 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
LCLivia Carrascal
Livia Carrascal
PEDRO NUNEZ ABADESPEDRO NUNEZ ABADES
PEDRO NUNEZ ABADES
AAAntonio Ayala
Antonio Ayala
MCMercedes Cano
Mercedes Cano
Melatonin is an indolamine synthesized and secreted by the pineal gland along with other extrapineal sources including immune system cells, the brain, skin and the gastrointestinal tract. Growing interest in this compound as a potential therapeutic agent in several diseases stems from its pleiotropic effects. Thus, melatonin plays a key role in various physiological activities that include regulation of circadian rhythms, immune responses, the oxidative process, apoptosis or mitochondrial homeostasis. Most of these processes are altered during inflammatory pathologies, among which neurodegenerative and bowel diseases stand out. Therapeutic assays with melatonin indicate that it has a beneficial therapeutic value in the treatment of several inflammatory diseases, such as Alzheimer, Amiotrophic Lateral, Multiple Sclerosis and Huntigton´s disease as well as ulcerative colitis. However, contradictory effects have been demonstrated in Parkinson´s and Chron´s diseases, which, in some cases, the reported effects were beneficial while in others the pathology was exacerbated. These various results may be related to several factors. In the first place, it should be taken into account that at the beginning of the inflammation phase there is a production of reactive oxygen species (ROS) that should not be blocked by exclusively antioxidant molecules, since, on the one hand, it would be interfering with the action of neutrophils and macrophages and, on the other, with the apoptotic signals activated by ROS. It is also important to keep in mind that the end result of an anti-inflammatory molecule will depend on the degree of inflammation or whether or not it has been resolved and has therefore become chronic. In this review we present the use of melatonin in the control of inflammation underlying the above mentioned diseases. These actions are mediated through their receptors but also with their direct antioxidant action and melatonin's ability to break the vicious cycle of ROSinflammation. This review is aimed at evaluating the effect of melatonin on activity of the inflammatory process and at its immunomodulator effects.

6 March 2019 in Annals of the New York Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SASandro Arguelles
Sandro Arguelles
AGANGELICA GUERRERO
ANGELICA GUERRERO
MCMercedes Cano
Mercedes Cano
MMMario F. Muñoz
Mario F. Muñoz
AAAntonio Ayala
Antonio Ayala

1 May 2019 in Pharmacological Research
Verified
Journal Article
Closed access
YYYiu To Yeung
Yiu To Yeung
AGANGELICA GUERRERO
ANGELICA GUERRERO
MCMercedes Cano
Mercedes Cano
MMMario F. Muñoz
Mario F. Muñoz
AAAntonio Ayala
Antonio Ayala
SASandro Arguelles
Sandro Arguelles

12 December 2022 in Expert Reviews in Molecular Medicine
Verified
Journal Article
Open access
PDF file
BSBegoña Sánchez
Begoña Sánchez
MMMario F. Muñoz-Pinto
Mario F. Muñoz-Pinto
MCMercedes Cano
Mercedes Cano
Ageing is characterised by the accumulation of molecular and cellular damage through time, leading to a decline in physical and mental abilities. Currently, society has experienced a rapid increase in life expectancy, which has led to an increase in age-associated diseases. Therefore, it is crucial to study the process of ageing to guarantee the best conditions in the final stages of life. In recent years, interest has increased in a myokine known as irisin, which is secreted during physical exercise. This polypeptide hormone is produced by various organs, mainly muscle, and once it is released into the blood, it performs a wide variety of functions that are involved in metabolic control and may be relevant during some of the diseases associated with ageing. The aim of this review is to highlight the recent studies of irisin, such as its mechanism of expression, blood release, distribution, tissue target and participation in various cellular metabolic reactions and the relationship with key anti-ageing pathways such as adenosine monophosphate-activated protein kinase, silent information regulator T 1, autophagy and telomerase. In conclusion, irisin is a key player during the ageing process and it could be a novel target molecule for the therapeutic approach to boost longevity pathways. However, more research will be necessary to use this promising hormone for this gain.

1 September 2019 in Food and Chemical Toxicology
Verified
Journal Article
Closed access
MCMercedes Cano
Mercedes Cano
AGANGELICA GUERRERO
ANGELICA GUERRERO
SNSeyed Mohammad Nabavi
Seyed Mohammad Nabavi
AAAntonio Ayala
Antonio Ayala
SASandro Arguelles
Sandro Arguelles